

**510(k) Summary****JUN 21 2013**

**Date:** 21 September 2012  
**Sponsor:** ulrich GmbH & Co. KG  
Buchbrunnenweg 12  
89081 Ulm  
Germany  
Phone: +49 (0) 731-9654-1304  
Fax: +49 (0) 731-9654-2802

**Contact Person:** Hans Stover  
ulrich medical USA, Inc.  
612 Trade Center Blvd.  
Chesterfield, MO 63005  
(636) 519-0268 Office  
(636) 519-0271 Fax

**Proposed Trade Name:** tezo™ Titanium Cage Family

**Device Classification** Class II

**Classification Name:** Intervertebral body fusion device

**Regulation:** 888.3080

**Device Product Code:** MAX

**Device Description:** The tezo™ Titanium Cage Family is comprised of three principal interbody fusion cages. The tezo-P and tezo-T devices have a basic rectangular shape while the tezo-A device has a basic kidney shape. All implants have a hollow center for placement of autograft. The tezo implants are available in an assortment of height, length, width and anteroposterior angulation combinations to accommodate a variety of anatomic requirements

**Intended Use:** tezo™ is indicated for intervertebral body fusion of the lumbar spine, from L2 to S1, in skeletally mature patients who have had six months of non-operative treatment. The device is intended for use at either one level or two contiguous levels for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis or retrolisthesis. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The device is intended for use with supplemental fixation and with autograft to facilitate fusion.

**Materials:** tezo™ devices are manufactured from Ti-6Al-4V titanium alloy which conforms to ASTM F136.

<b>Predicate Devices:</b>	pezo™ PEEK Cage Family – K103814 Fuse Cage – K100945 and K121288
<b>Technological Characteristics:</b>	<p>tezo™ possesses the same technological characteristics as one or more of the predicate devices. These include:</p> <ul style="list-style-type: none"> <li>• intended use (as described above)</li> <li>• basic design (hollow structure for the containment of autograft),</li> <li>• material (titanium),</li> <li>• manufacturing (additive)</li> <li>• sizes (dimensions are comparable to those offered by the predicate systems) and</li> </ul> <p>The fundamental scientific technology of tezo™ is the same as previously cleared devices.</p>
<b>Performance Data:</b>	<p>Mechanical testing of the worst case tezo™ device included static and dynamic compression according to ASTM F2077 and subsidence according to ASTM F2267.</p> <p>The mechanical test results demonstrate that tezo™ is substantially equivalent to the predicate devices and therefore that tezo™ is as safe and as effective as the predicate devices.</p>



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center - WO66-G0019  
Silver Spring, MD 20993-0012

ulrich GmbH & Co. KG  
% ulrich medical USA, Incorporated  
Mr. Hans Stover  
President and CEO  
612 Trade Center Boulevard  
Chesterfield, Missouri 63005

June 21, 2013

Re: K122957  
Trade/Device Name: tezo™ Titanium Cage Family  
Regulation Number: 21 CFR 888.3080  
Regulation Name: Intervertebral body fusion device  
Regulatory Class: Class II  
Product Code: MAX  
Dated: June 11, 2013  
Received: June 12, 2013

Dear Mr. Stover:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

**Anton E. Dmitriev**

For Mark N. Melkerson  
Director  
Division of Orthopedic Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## **Indications for Use Statement**

510(k) Number: K122957

Device Name: **tezo™ Titanium Cage Family**

Indications for Use:

tezo™ is indicated for intervertebral body fusion of the lumbar spine, from L2 to S1, in skeletally mature patients who have had six months of non-operative treatment. The device is intended for use at either one level or two contiguous levels for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis or retrolisthesis. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The device is intended for use with supplemental fixation and with autograft to facilitate fusion.

Prescription Use   X  

AND/OR

Over-the-Counter Use           

(21 CFR 801 Subpart D)

(21 CFR 807 Subpart C)

---

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Anton E. Dmitriev, PhD

Division of Orthopedic Devices